BMT CTN Protocol 1401

A Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell/Myeloma Fusions.

Below are protocol-related documents, which may be periodically updated.

             Protocol Co-Chair: David Avigan, MD davigan@bidmc.harvard.edu

             Protocol Co-Chair: Nina Shah, MD nina.shah@ucsf.edu

             Protocol Co-Chair: David Chung, MD ChungD1@mskcc.org

             Protocol Officer: Marcelo Pasquini, MD mpasquini@mcw.edu

             Medical Monitor: Marcie Riches, MD marcie_riches@med.unc.edu

             Protocol Coordinator: Kelly O'Brien, PhD bmtctn1401@emmes.com        

The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study. The protocol closed to enrollment on October 12, 2018.